Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement.
Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement.
复制标题
DOI：
10.1016/s2352-4642(21)00336-9
复制
发表时间：
2022-03
影响因子：
36.4
通讯作者：
Mahadeo, Kris M.
中科院分区：
文献类型：
--
作者：
Di Nardo, Matteo;Ahmad, Ali H.;Merli, Pietro;Zinter, Matthew S.;Lehman, Leslie E.;Rowan, Courtney M.;Steiner, Marie E.;Hingorani, Sangeeta;Angelo, Joseph R.;Abdel-Azim, Hisham;Khazal, Sajad J.;Shoberu, Basirat;McArthur, Jennifer;Bajwa, Rajinder;Ghafoor, Saad;Shah, Samir H.;Sandhu, Hitesh;Moody, Karen;Brown, Brandon D.;Mireles, Maria E.;Steppan, Diana;Olson, Taylor;Raman, Lakshmi;Bridges, Brian;Duncan, Christine N.;Choi, Sung Won;Swinford, Rita;Paden, Matt;Fortenberry, James D.;Peek, Giles;Tissieres, Pierre;De Luca, Daniele;Locatelli, Franco;Corbacioglu, Selim;Kneyber, Martin;Franceschini, Alessio;Nadel, Simon;Kumpf, Matthias;Loreti, Alessandra;Wosten-Van Asperen, Roelie;Gawronski, Orsola;Brierley, Joe;MacLaren, Graeme;Mahadeo, Kris M.
在接受造血细胞移植（HCT）和/或免疫效应细胞（IEC）的儿童中使用体外膜肺氧合（ECMO）仍然存在争议，缺乏循证指南。HCT和IEC疗法的显著进步改变了对受影响患者器官功能障碍可逆性和预期寿命的预期。在此，体外生命支持组织（ELSO）、儿科急性肺损伤和脓毒症研究者（PALISI）网络的成员-（HCT和癌症免疫治疗亚组），欧洲血液和骨髓移植学会（EBMT）儿科疾病工作组，儿科移植和细胞治疗联盟（PTCTC）的支持性护理委员会和欧洲儿科和新生儿重症监护协会（ESPNIC）的欧洲儿科重症监护肿瘤儿童研究（POKER）小组就ECMO在接受HCT-IEC的儿童中的使用提供了共识建议。这是关于在HCT-IEC儿科患者中使用ECMO的第一个国际多学科共识建议。在ECMO候选人和管理的艰难决策过程中，该手稿可作为儿科血液学家、肿瘤学家和重症监护医生的临床决策支持工具。这些建议可能是未来重点关注ECMO选择标准和床边管理的研究的基础。
Use of extracorporeal membrane oxygenation (ECMO) in children receiving hematopoietic cell transplantation (HCT) and/or Immune Effector Cells (IEC) remains controversial and evidence-based guidelines are lacking. Remarkable advancements in HCT and IEC therapies have changed expectations around reversibility of organ dysfunction and life-expectancy for affected patients. Herein, members of the Extracorporeal Life Support Organization (ELSO), Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network- (HCT and Cancer Immunotherapy Subgroup), the Pediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation (EBMT), the supportive care committee of the Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) and the Pediatric Intensive Care Oncology Kids in Europe Research (POKER) group of the European Society of Pediatric and Neonatal Intensive Care (ESPNIC) provide consensus recommendations on the use of ECMO in children receiving HCT-IEC. These are the first international, multi-disciplinary consensus-based recommendations on the use of ECMO in HCT-IEC pediatric patients. This manuscript may serve as a clinical decision support tool for pediatric hematologists, oncologists, and critical care physicians during the difficult decision-making process of ECMO candidacy and management. These recommendations may represent a base for future research studies focused on ECMO selection criteria and bedside management.